The FDA has granted diagnostics company IDx’s De Novo request to market its AI-based software system for the autonomous detection of diabetic retinopathy in adults who have diabetes, called IDx-DR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback